{"gene":"DRD5","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2020,"finding":"DRD5 receptor directly recruits TRAF6 and its negative regulator ARRB2 via the EFD and IYX(X)I/L motifs in its C-terminal and IC3 loop, respectively, forming a multi-protein complex containing TAK1, IKKs, and PP2A, which impairs TRAF6-mediated NF-κB activation and pro-inflammatory gene expression in macrophages. Dopamine signaling through DRD5 activates this ARRB2-PP2A axis to suppress TLR2-induced NF-κB signaling and protect against S. aureus-induced sepsis and meningitis.","method":"Co-immunoprecipitation, motif mutagenesis, in vitro signaling assays, mouse infection models (S. aureus sepsis and meningitis), genetic knockdown/knockout","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying specific motifs, mutagenesis, multiple orthogonal methods (cell-based signaling assays + in vivo mouse models), rigorous mechanistic delineation","pmids":["32035036"],"is_preprint":false},{"year":2017,"finding":"DRD5 activation increases reactive oxygen species (ROS) production, inhibits the mTOR pathway, and induces macroautophagy/autophagy leading to autophagic cell death (ACD) in pituitary tumor cells and other cancer cell lines (glioblastoma, colon cancer, gastric cancer) both in vitro and in vivo.","method":"DRD5 agonist (SKF83959) treatment of pituitary tumor cell cultures and other cancer cell lines; ROS measurement; mTOR pathway analysis; autophagy assays; xenograft mouse model (human gastric cancer in nude mice); correlation of efficacy with DRD5 expression levels","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays with multiple cancer cell types, single lab, no genetic rescue or receptor-null controls explicitly stated in abstract","pmids":["28613975"],"is_preprint":false},{"year":2021,"finding":"DA-DRD5 signaling in colonic macrophages inhibits M1 polarization by negatively regulating NF-κB signaling and promotes M2 macrophage polarization through activation of the CREB pathway; DRD5 deficiency exacerbates experimental colitis by increasing M1 and reducing M2 macrophages.","method":"DRD5 knockout mouse model, experimental colitis model, macrophage polarization assays, NF-κB and CREB pathway analysis, D1-like agonist treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with defined cellular phenotype and pathway analysis, single lab, two signaling pathways assessed","pmids":["34001860"],"is_preprint":false},{"year":2021,"finding":"DRD5 (D5R) expression in the left ventricle decreases progressively with worsening left ventricular hypertrophy; cardiac-specific restoration of D5R expression attenuates hypertrophy and fibrosis by preventing oxidative stress, ER stress, and autophagic dysregulation, while siRNA-mediated knockdown of Drd5 accelerates progression to heart failure.","method":"Transverse aortic constriction (TAC) mouse model, Drd5 plasmid/siRNA delivery via polyaminoglycoside nanoparticle, cardiac function assessment, oxidative/ER stress markers, autophagy assays, validation in human hypertrophic cardiomyopathy samples","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in vivo with defined mechanistic endpoints, single lab, validated in human tissue","pmids":["33717857"],"is_preprint":false},{"year":2021,"finding":"DRD5-mediated dopamine signaling in esophageal cancer cells enhances glucose uptake, lactate production, and extracellular acidification rate (Warburg effect) via cross-talk between the mTOR and AKT pathways, promoting tumor cell proliferation and growth.","method":"In vitro cancer cell proliferation assays, glucose uptake and lactate measurement, ECAR measurement (Seahorse), mTOR/AKT pathway analysis, in vivo xenograft experiments, DRD5 expression analysis in patient tumor tissues","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro and in vivo functional assays with metabolic readouts, single lab, pathway placement via inhibitor studies inferred from abstract","pmids":["33898321"],"is_preprint":false},{"year":2025,"finding":"DRD5 signaling in B cells activates JAK1-STAT1 signaling, enhancing B cell activation, antigen presentation, and co-stimulation, which results in increased expansion and cytotoxicity of tumor-specific effector CD8+ T cells, thereby suppressing tumor progression.","method":"DRD5-dependent B cell signaling assays, JAK1-STAT1 pathway analysis, co-culture experiments, in vivo tumor models, correlation of DA levels with B cell numbers","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific signaling pathway identified with functional immune readouts, single lab, single study","pmids":["40023842"],"is_preprint":false},{"year":2019,"finding":"In primary pituitary tumor cells with low DRD2 expression and high DRD5 expression, a DRD5-specific agonist (SKF38393) inhibits tumor cell growth with 70% efficacy, indicating that DRD5 can function as an alternative therapeutic target to DRD2 in dopamine agonist-resistant pituitary tumors.","method":"Immunohistochemistry for receptor expression in human pituitary tumor tissue, MTS cell viability assay with DRD5 agonist SKF38393 vs. DRD2 agonist and cabergoline in primary pituitary tumor cell cultures","journal":"Zhonghua yi xue za zhi","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological agonist in primary cell cultures, no genetic controls, single lab, correlative receptor expression","pmids":["31216815"],"is_preprint":false},{"year":1993,"finding":"The human DRD5 gene was mapped to chromosome 4p15.1-p15.3 by in situ hybridization and somatic cell hybrid panel analysis; a highly polymorphic dinucleotide repeat sequence in the cosmid clone showed tight linkage to the chromosome 4p reference marker RAF1P1.","method":"In situ hybridization, somatic cell hybrid panel, linkage analysis in CEPH pedigrees","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — direct chromosomal localization by two independent methods (in situ hybridization and somatic cell hybrids), replicated by linkage analysis","pmids":["8288248"],"is_preprint":false}],"current_model":"DRD5 is a G protein-coupled dopamine receptor that, upon activation, engages multiple downstream signaling pathways: it recruits TRAF6, ARRB2, and PP2A via defined intracellular motifs to suppress NF-κB-driven inflammation; activates JAK1-STAT1 in B cells to enhance antitumor immunity; inhibits mTOR to induce autophagic cell death in tumor cells; regulates M1/M2 macrophage polarization via NF-κB and CREB; and in the heart, its expression loss promotes oxidative/ER stress and autophagic dysregulation leading to ventricular hypertrophy."},"narrative":{"mechanistic_narrative":"DRD5 is a D1-like G protein-coupled dopamine receptor whose activation translates dopamine signaling into control of inflammation, immunity, autophagy, and tissue homeostasis [PMID:32035036, PMID:34001860]. In macrophages, the receptor uses its EFD motif and an IYX(X)I/L motif in its C-terminus and third intracellular loop to recruit TRAF6 together with its negative regulator ARRB2, assembling a complex containing TAK1, IKKs, and PP2A that impairs TRAF6-mediated NF-κB activation; through this ARRB2-PP2A axis dopamine-DRD5 signaling suppresses TLR2-driven pro-inflammatory gene expression and protects against S. aureus sepsis and meningitis [PMID:32035036]. DRD5 signaling also shapes macrophage fate, restraining M1 polarization via NF-κB while promoting M2 polarization through CREB, such that receptor deficiency worsens experimental colitis [PMID:34001860]. In the tumor context the receptor exerts dual outputs: agonist-driven DRD5 activation raises ROS, inhibits mTOR, and induces autophagic cell death in pituitary and other cancer cells [PMID:28613975], and DRD5 signaling in B cells engages JAK1-STAT1 to enhance antigen presentation and expand cytotoxic CD8+ T cells [PMID:40023842]. In the heart, progressive loss of D5R expression accompanies ventricular hypertrophy, and restoring D5R attenuates hypertrophy and fibrosis by limiting oxidative stress, ER stress, and autophagic dysregulation [PMID:33717857]. The human gene maps to chromosome 4p15.1-p15.3 [PMID:8288248].","teleology":[{"year":1993,"claim":"Before functional characterization, the genomic position of DRD5 was unknown; mapping it provided the chromosomal anchor and a polymorphic marker for subsequent genetic studies.","evidence":"In situ hybridization and somatic cell hybrid panel with linkage analysis in CEPH pedigrees","pmids":["8288248"],"confidence":"Medium","gaps":["Establishes location but no protein function","No link to any phenotype or signaling pathway"]},{"year":2017,"claim":"It was unclear how DRD5 activation affects tumor cell viability; agonist treatment showed it raises ROS, inhibits mTOR, and triggers autophagic cell death, defining a pro-death signaling output.","evidence":"DRD5 agonist (SKF83959) on pituitary and other cancer cell lines with ROS/mTOR/autophagy assays and gastric cancer xenografts","pmids":["28613975"],"confidence":"Medium","gaps":["No genetic rescue or receptor-null controls cited","G protein coupling and proximal effectors of the mTOR-autophagy axis not defined"]},{"year":2019,"claim":"Whether DRD5 could substitute for DRD2 in dopamine-resistant pituitary tumors was untested; a DRD5-specific agonist inhibited growth in tumors with high DRD5 and low DRD2, nominating DRD5 as an alternative target.","evidence":"Immunohistochemistry and MTS viability assays with SKF38393 in primary human pituitary tumor cultures","pmids":["31216815"],"confidence":"Low","gaps":["Pharmacological agonist without genetic controls","Correlative receptor expression only","Mechanism of growth inhibition not delineated"]},{"year":2020,"claim":"How dopamine signaling restrains inflammation was unresolved; this work mapped specific DRD5 motifs recruiting TRAF6, ARRB2, and PP2A to suppress NF-κB, establishing a receptor-intrinsic anti-inflammatory mechanism with in vivo protection.","evidence":"Reciprocal Co-IP, motif mutagenesis, cell-based signaling assays, and mouse S. aureus sepsis/meningitis models with knockdown/knockout","pmids":["32035036"],"confidence":"High","gaps":["Structural basis of motif-effector recognition not resolved","Whether the same complex operates in non-macrophage cell types untested"]},{"year":2021,"claim":"The role of DRD5 in macrophage fate was unknown; knockout studies showed DRD5 inhibits M1 via NF-κB and drives M2 via CREB, linking the receptor to mucosal inflammatory balance.","evidence":"Drd5 knockout mice, experimental colitis, macrophage polarization assays, NF-κB/CREB analysis, D1-like agonist","pmids":["34001860"],"confidence":"Medium","gaps":["Connection between the CREB arm and the TRAF6-PP2A complex unresolved","Single lab, two pathways assessed"]},{"year":2021,"claim":"DRD5's role in cardiac remodeling was unaddressed; gain- and loss-of-function in vivo showed D5R expression protects against hypertrophy by limiting oxidative/ER stress and autophagic dysregulation.","evidence":"TAC mouse model with Drd5 plasmid/siRNA nanoparticle delivery, stress and autophagy markers, human hypertrophic cardiomyopathy validation","pmids":["33717857"],"confidence":"Medium","gaps":["Downstream effectors linking D5R to ER stress control unclear","Causal direction of expression loss versus hypertrophy not fully separated"]},{"year":2021,"claim":"A contrasting pro-tumor role emerged in esophageal cancer, where DRD5 signaling enhanced the Warburg effect via mTOR-AKT crosstalk to promote proliferation, indicating context-dependent metabolic outputs.","evidence":"Proliferation, glucose uptake, lactate, ECAR (Seahorse), mTOR/AKT inhibitor studies, xenografts, patient tumor expression","pmids":["33898321"],"confidence":"Medium","gaps":["Reconciliation with autophagic cell death output in other cancers unresolved","Pathway placement inferred from inhibitor studies"]},{"year":2025,"claim":"Whether DRD5 contributes to antitumor immunity beyond myeloid cells was open; B cell DRD5 signaling was shown to activate JAK1-STAT1 to boost antigen presentation and CD8+ T cell expansion.","evidence":"B cell signaling assays, JAK1-STAT1 analysis, co-culture, in vivo tumor models, dopamine-B cell correlation","pmids":["40023842"],"confidence":"Medium","gaps":["Direct receptor-to-JAK1 coupling mechanism not defined","Single study, single lab"]},{"year":null,"claim":"It remains unresolved how a single receptor produces opposing outputs across tissues, including pro-death autophagy versus Warburg-promoting proliferation and anti- versus pro-inflammatory effects.","evidence":"","pmids":[],"confidence":"Medium","gaps":["G protein coupling specificity across cell types undefined","No structural model of effector recruitment","Determinants of context-dependent mTOR outcome unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,5]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[1,3]}],"complexes":[],"partners":["TRAF6","ARRB2","PP2A","TAK1","IKK","JAK1","STAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21918","full_name":"D(1B) dopamine receptor","aliases":["D(5) dopamine receptor","D1beta dopamine receptor","Dopamine D5 receptor"],"length_aa":477,"mass_kda":53.0,"function":"Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P21918/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DRD5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DRD5","total_profiled":1310},"omim":[{"mim_id":"611240","title":"GPRIN FAMILY, MEMBER 2; GPRIN2","url":"https://www.omim.org/entry/611240"},{"mim_id":"610813","title":"HYDIN AXONEMAL CENTRAL PAIR APPARATUS PROTEIN 2; HYDIN2","url":"https://www.omim.org/entry/610813"},{"mim_id":"610501","title":"NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 1; NBPF1","url":"https://www.omim.org/entry/610501"},{"mim_id":"606798","title":"BLEPHAROSPASM, BENIGN ESSENTIAL, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/606798"},{"mim_id":"606793","title":"AMINOPEPTIDASE, PUROMYCIN-SENSITIVE; NPEPPS","url":"https://www.omim.org/entry/606793"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":2.6},{"tissue":"lymphoid tissue","ntpm":1.3},{"tissue":"stomach 1","ntpm":4.2}],"url":"https://www.proteinatlas.org/search/DRD5"},"hgnc":{"alias_symbol":["DRD1B"],"prev_symbol":["DRD1L2"]},"alphafold":{"accession":"P21918","domains":[{"cath_id":"1.20.1070.10","chopping":"38-183_216-270_286-324_344-374","consensus_level":"medium","plddt":88.1078,"start":38,"end":374}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21918","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21918-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21918-F1-predicted_aligned_error_v6.png","plddt_mean":69.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DRD5","jax_strain_url":"https://www.jax.org/strain/search?query=DRD5"},"sequence":{"accession":"P21918","fasta_url":"https://rest.uniprot.org/uniprotkb/P21918.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21918/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21918"}},"corpus_meta":[{"pmid":"10208453","id":"PMC_10208453","title":"Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children.","date":"1999","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10208453","citation_count":285,"is_preprint":false},{"pmid":"14732906","id":"PMC_14732906","title":"Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes.","date":"2004","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14732906","citation_count":130,"is_preprint":false},{"pmid":"12660802","id":"PMC_12660802","title":"Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci.","date":"2003","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12660802","citation_count":89,"is_preprint":false},{"pmid":"28613975","id":"PMC_28613975","title":"Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.","date":"2017","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/28613975","citation_count":80,"is_preprint":false},{"pmid":"32035036","id":"PMC_32035036","title":"Dopamine Uses the DRD5-ARRB2-PP2A Signaling Axis to Block the TRAF6-Mediated NF-κB Pathway and Suppress Systemic Inflammation.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32035036","citation_count":77,"is_preprint":false},{"pmid":"14699430","id":"PMC_14699430","title":"Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5.","date":"2004","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/14699430","citation_count":77,"is_preprint":false},{"pmid":"18081165","id":"PMC_18081165","title":"Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18081165","citation_count":72,"is_preprint":false},{"pmid":"15578613","id":"PMC_15578613","title":"Quantitative trait locus analysis of candidate gene alleles associated with attention deficit hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25, and 5HT1B.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15578613","citation_count":66,"is_preprint":false},{"pmid":"8288248","id":"PMC_8288248","title":"Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8288248","citation_count":54,"is_preprint":false},{"pmid":"20714340","id":"PMC_20714340","title":"Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.","date":"2010","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/20714340","citation_count":51,"is_preprint":false},{"pmid":"34001860","id":"PMC_34001860","title":"DA-DRD5 signaling controls colitis by regulating colonic M1/M2 macrophage polarization.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34001860","citation_count":45,"is_preprint":false},{"pmid":"11781417","id":"PMC_11781417","title":"A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm.","date":"2002","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11781417","citation_count":43,"is_preprint":false},{"pmid":"15389755","id":"PMC_15389755","title":"DAT1, DRD4, and DRD5 polymorphisms are not associated with ADHD in Dutch families.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15389755","citation_count":40,"is_preprint":false},{"pmid":"9583233","id":"PMC_9583233","title":"An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study.","date":"1998","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9583233","citation_count":40,"is_preprint":false},{"pmid":"11353446","id":"PMC_11353446","title":"An association study of DRD5 with smoking initiation and progression to nicotine dependence.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11353446","citation_count":38,"is_preprint":false},{"pmid":"17133500","id":"PMC_17133500","title":"Assessing the role of DRD5 and DYT1 in two different case-control series with primary blepharospasm.","date":"2007","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/17133500","citation_count":38,"is_preprint":false},{"pmid":"11304828","id":"PMC_11304828","title":"Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11304828","citation_count":34,"is_preprint":false},{"pmid":"25556472","id":"PMC_25556472","title":"Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25556472","citation_count":27,"is_preprint":false},{"pmid":"33717857","id":"PMC_33717857","title":"Reversible Treatment of Pressure Overload-Induced Left Ventricular Hypertrophy through Drd5 Nucleic Acid Delivery Mediated by Functional Polyaminoglycoside.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33717857","citation_count":22,"is_preprint":false},{"pmid":"14755441","id":"PMC_14755441","title":"Polymorphisms in the dopamine D5 receptor (DRD5) gene and ADHD.","date":"2004","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14755441","citation_count":19,"is_preprint":false},{"pmid":"12700316","id":"PMC_12700316","title":"Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia.","date":"2003","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12700316","citation_count":18,"is_preprint":false},{"pmid":"11054773","id":"PMC_11054773","title":"Antisociality, substance dependence, and the DRD5 gene: a preliminary study.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11054773","citation_count":18,"is_preprint":false},{"pmid":"17301410","id":"PMC_17301410","title":"The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR.","date":"2004","source":"Iranian journal of allergy, asthma, and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17301410","citation_count":17,"is_preprint":false},{"pmid":"24668635","id":"PMC_24668635","title":"Relationship between genetic polymorphisms in the DRD5 gene and paranoid schizophrenia in northern Han Chinese.","date":"2014","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24668635","citation_count":16,"is_preprint":false},{"pmid":"33898321","id":"PMC_33898321","title":"Dopamine Pathway Mediated by DRD5 Facilitates Tumor Growth via Enhancing Warburg Effect in Esophageal Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33898321","citation_count":15,"is_preprint":false},{"pmid":"8540565","id":"PMC_8540565","title":"Linkage study of the D5 dopamine receptor gene (DRD5) in multiplex Icelandic and English schizophrenia pedigrees.","date":"1996","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/8540565","citation_count":13,"is_preprint":false},{"pmid":"18164132","id":"PMC_18164132","title":"Investigation of the dopamine D5 receptor gene (DRD5) in adult attention deficit hyperactivity disorder.","date":"2007","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/18164132","citation_count":12,"is_preprint":false},{"pmid":"19397556","id":"PMC_19397556","title":"SNP discovery and haplotype analysis in the segmentally duplicated DRD5 coding region.","date":"2009","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19397556","citation_count":9,"is_preprint":false},{"pmid":"27480019","id":"PMC_27480019","title":"Meta-analysis of the DRD5 VNTR in persistent ADHD.","date":"2016","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27480019","citation_count":5,"is_preprint":false},{"pmid":"26909995","id":"PMC_26909995","title":"Bovine dopamine receptors DRD1, DRD4, and DRD5: genetic polymorphisms and diversities among ten cattle breeds.","date":"2016","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26909995","citation_count":4,"is_preprint":false},{"pmid":"32907377","id":"PMC_32907377","title":"Hypermethylation of DRD5 Promoter Is a Biomarker Across 12 Cancer Types.","date":"2020","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32907377","citation_count":4,"is_preprint":false},{"pmid":"40023842","id":"PMC_40023842","title":"DA-DRD5 signaling reprograms B cells to promote CD8+ T cell-mediated antitumor immunity.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40023842","citation_count":3,"is_preprint":false},{"pmid":"31216815","id":"PMC_31216815","title":"[Role of dopamine receptor subtypes DRD2 and DRD5 in drug therapy of pituitary tumors].","date":"2019","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31216815","citation_count":1,"is_preprint":false},{"pmid":"29936463","id":"PMC_29936463","title":"A Study of Short- and Long-term mRNA Levels of the Retn, Iapp, and Drd5 Genes in Obese Mice Induced with High-fat Diet.","date":"2018","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/29936463","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16663,"output_tokens":2223,"usd":0.041667,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9302,"output_tokens":3041,"usd":0.061268,"stage2_stop_reason":"end_turn"},"total_usd":0.102935,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"DRD5 receptor directly recruits TRAF6 and its negative regulator ARRB2 via the EFD and IYX(X)I/L motifs in its C-terminal and IC3 loop, respectively, forming a multi-protein complex containing TAK1, IKKs, and PP2A, which impairs TRAF6-mediated NF-κB activation and pro-inflammatory gene expression in macrophages. Dopamine signaling through DRD5 activates this ARRB2-PP2A axis to suppress TLR2-induced NF-κB signaling and protect against S. aureus-induced sepsis and meningitis.\",\n      \"method\": \"Co-immunoprecipitation, motif mutagenesis, in vitro signaling assays, mouse infection models (S. aureus sepsis and meningitis), genetic knockdown/knockout\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying specific motifs, mutagenesis, multiple orthogonal methods (cell-based signaling assays + in vivo mouse models), rigorous mechanistic delineation\",\n      \"pmids\": [\"32035036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DRD5 activation increases reactive oxygen species (ROS) production, inhibits the mTOR pathway, and induces macroautophagy/autophagy leading to autophagic cell death (ACD) in pituitary tumor cells and other cancer cell lines (glioblastoma, colon cancer, gastric cancer) both in vitro and in vivo.\",\n      \"method\": \"DRD5 agonist (SKF83959) treatment of pituitary tumor cell cultures and other cancer cell lines; ROS measurement; mTOR pathway analysis; autophagy assays; xenograft mouse model (human gastric cancer in nude mice); correlation of efficacy with DRD5 expression levels\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays with multiple cancer cell types, single lab, no genetic rescue or receptor-null controls explicitly stated in abstract\",\n      \"pmids\": [\"28613975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DA-DRD5 signaling in colonic macrophages inhibits M1 polarization by negatively regulating NF-κB signaling and promotes M2 macrophage polarization through activation of the CREB pathway; DRD5 deficiency exacerbates experimental colitis by increasing M1 and reducing M2 macrophages.\",\n      \"method\": \"DRD5 knockout mouse model, experimental colitis model, macrophage polarization assays, NF-κB and CREB pathway analysis, D1-like agonist treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with defined cellular phenotype and pathway analysis, single lab, two signaling pathways assessed\",\n      \"pmids\": [\"34001860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DRD5 (D5R) expression in the left ventricle decreases progressively with worsening left ventricular hypertrophy; cardiac-specific restoration of D5R expression attenuates hypertrophy and fibrosis by preventing oxidative stress, ER stress, and autophagic dysregulation, while siRNA-mediated knockdown of Drd5 accelerates progression to heart failure.\",\n      \"method\": \"Transverse aortic constriction (TAC) mouse model, Drd5 plasmid/siRNA delivery via polyaminoglycoside nanoparticle, cardiac function assessment, oxidative/ER stress markers, autophagy assays, validation in human hypertrophic cardiomyopathy samples\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in vivo with defined mechanistic endpoints, single lab, validated in human tissue\",\n      \"pmids\": [\"33717857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DRD5-mediated dopamine signaling in esophageal cancer cells enhances glucose uptake, lactate production, and extracellular acidification rate (Warburg effect) via cross-talk between the mTOR and AKT pathways, promoting tumor cell proliferation and growth.\",\n      \"method\": \"In vitro cancer cell proliferation assays, glucose uptake and lactate measurement, ECAR measurement (Seahorse), mTOR/AKT pathway analysis, in vivo xenograft experiments, DRD5 expression analysis in patient tumor tissues\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro and in vivo functional assays with metabolic readouts, single lab, pathway placement via inhibitor studies inferred from abstract\",\n      \"pmids\": [\"33898321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DRD5 signaling in B cells activates JAK1-STAT1 signaling, enhancing B cell activation, antigen presentation, and co-stimulation, which results in increased expansion and cytotoxicity of tumor-specific effector CD8+ T cells, thereby suppressing tumor progression.\",\n      \"method\": \"DRD5-dependent B cell signaling assays, JAK1-STAT1 pathway analysis, co-culture experiments, in vivo tumor models, correlation of DA levels with B cell numbers\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific signaling pathway identified with functional immune readouts, single lab, single study\",\n      \"pmids\": [\"40023842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In primary pituitary tumor cells with low DRD2 expression and high DRD5 expression, a DRD5-specific agonist (SKF38393) inhibits tumor cell growth with 70% efficacy, indicating that DRD5 can function as an alternative therapeutic target to DRD2 in dopamine agonist-resistant pituitary tumors.\",\n      \"method\": \"Immunohistochemistry for receptor expression in human pituitary tumor tissue, MTS cell viability assay with DRD5 agonist SKF38393 vs. DRD2 agonist and cabergoline in primary pituitary tumor cell cultures\",\n      \"journal\": \"Zhonghua yi xue za zhi\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological agonist in primary cell cultures, no genetic controls, single lab, correlative receptor expression\",\n      \"pmids\": [\"31216815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The human DRD5 gene was mapped to chromosome 4p15.1-p15.3 by in situ hybridization and somatic cell hybrid panel analysis; a highly polymorphic dinucleotide repeat sequence in the cosmid clone showed tight linkage to the chromosome 4p reference marker RAF1P1.\",\n      \"method\": \"In situ hybridization, somatic cell hybrid panel, linkage analysis in CEPH pedigrees\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct chromosomal localization by two independent methods (in situ hybridization and somatic cell hybrids), replicated by linkage analysis\",\n      \"pmids\": [\"8288248\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DRD5 is a G protein-coupled dopamine receptor that, upon activation, engages multiple downstream signaling pathways: it recruits TRAF6, ARRB2, and PP2A via defined intracellular motifs to suppress NF-κB-driven inflammation; activates JAK1-STAT1 in B cells to enhance antitumor immunity; inhibits mTOR to induce autophagic cell death in tumor cells; regulates M1/M2 macrophage polarization via NF-κB and CREB; and in the heart, its expression loss promotes oxidative/ER stress and autophagic dysregulation leading to ventricular hypertrophy.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DRD5 is a D1-like G protein-coupled dopamine receptor whose activation translates dopamine signaling into control of inflammation, immunity, autophagy, and tissue homeostasis [#0, #2]. In macrophages, the receptor uses its EFD motif and an IYX(X)I/L motif in its C-terminus and third intracellular loop to recruit TRAF6 together with its negative regulator ARRB2, assembling a complex containing TAK1, IKKs, and PP2A that impairs TRAF6-mediated NF-\\u03baB activation; through this ARRB2-PP2A axis dopamine-DRD5 signaling suppresses TLR2-driven pro-inflammatory gene expression and protects against S. aureus sepsis and meningitis [#0]. DRD5 signaling also shapes macrophage fate, restraining M1 polarization via NF-\\u03baB while promoting M2 polarization through CREB, such that receptor deficiency worsens experimental colitis [#2]. In the tumor context the receptor exerts dual outputs: agonist-driven DRD5 activation raises ROS, inhibits mTOR, and induces autophagic cell death in pituitary and other cancer cells [#1], and DRD5 signaling in B cells engages JAK1-STAT1 to enhance antigen presentation and expand cytotoxic CD8+ T cells [#5]. In the heart, progressive loss of D5R expression accompanies ventricular hypertrophy, and restoring D5R attenuates hypertrophy and fibrosis by limiting oxidative stress, ER stress, and autophagic dysregulation [#3]. The human gene maps to chromosome 4p15.1-p15.3 [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Before functional characterization, the genomic position of DRD5 was unknown; mapping it provided the chromosomal anchor and a polymorphic marker for subsequent genetic studies.\",\n      \"evidence\": \"In situ hybridization and somatic cell hybrid panel with linkage analysis in CEPH pedigrees\",\n      \"pmids\": [\"8288248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Establishes location but no protein function\", \"No link to any phenotype or signaling pathway\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"It was unclear how DRD5 activation affects tumor cell viability; agonist treatment showed it raises ROS, inhibits mTOR, and triggers autophagic cell death, defining a pro-death signaling output.\",\n      \"evidence\": \"DRD5 agonist (SKF83959) on pituitary and other cancer cell lines with ROS/mTOR/autophagy assays and gastric cancer xenografts\",\n      \"pmids\": [\"28613975\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic rescue or receptor-null controls cited\", \"G protein coupling and proximal effectors of the mTOR-autophagy axis not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Whether DRD5 could substitute for DRD2 in dopamine-resistant pituitary tumors was untested; a DRD5-specific agonist inhibited growth in tumors with high DRD5 and low DRD2, nominating DRD5 as an alternative target.\",\n      \"evidence\": \"Immunohistochemistry and MTS viability assays with SKF38393 in primary human pituitary tumor cultures\",\n      \"pmids\": [\"31216815\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pharmacological agonist without genetic controls\", \"Correlative receptor expression only\", \"Mechanism of growth inhibition not delineated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"How dopamine signaling restrains inflammation was unresolved; this work mapped specific DRD5 motifs recruiting TRAF6, ARRB2, and PP2A to suppress NF-\\u03baB, establishing a receptor-intrinsic anti-inflammatory mechanism with in vivo protection.\",\n      \"evidence\": \"Reciprocal Co-IP, motif mutagenesis, cell-based signaling assays, and mouse S. aureus sepsis/meningitis models with knockdown/knockout\",\n      \"pmids\": [\"32035036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of motif-effector recognition not resolved\", \"Whether the same complex operates in non-macrophage cell types untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The role of DRD5 in macrophage fate was unknown; knockout studies showed DRD5 inhibits M1 via NF-\\u03baB and drives M2 via CREB, linking the receptor to mucosal inflammatory balance.\",\n      \"evidence\": \"Drd5 knockout mice, experimental colitis, macrophage polarization assays, NF-\\u03baB/CREB analysis, D1-like agonist\",\n      \"pmids\": [\"34001860\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Connection between the CREB arm and the TRAF6-PP2A complex unresolved\", \"Single lab, two pathways assessed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"DRD5's role in cardiac remodeling was unaddressed; gain- and loss-of-function in vivo showed D5R expression protects against hypertrophy by limiting oxidative/ER stress and autophagic dysregulation.\",\n      \"evidence\": \"TAC mouse model with Drd5 plasmid/siRNA nanoparticle delivery, stress and autophagy markers, human hypertrophic cardiomyopathy validation\",\n      \"pmids\": [\"33717857\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors linking D5R to ER stress control unclear\", \"Causal direction of expression loss versus hypertrophy not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A contrasting pro-tumor role emerged in esophageal cancer, where DRD5 signaling enhanced the Warburg effect via mTOR-AKT crosstalk to promote proliferation, indicating context-dependent metabolic outputs.\",\n      \"evidence\": \"Proliferation, glucose uptake, lactate, ECAR (Seahorse), mTOR/AKT inhibitor studies, xenografts, patient tumor expression\",\n      \"pmids\": [\"33898321\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with autophagic cell death output in other cancers unresolved\", \"Pathway placement inferred from inhibitor studies\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Whether DRD5 contributes to antitumor immunity beyond myeloid cells was open; B cell DRD5 signaling was shown to activate JAK1-STAT1 to boost antigen presentation and CD8+ T cell expansion.\",\n      \"evidence\": \"B cell signaling assays, JAK1-STAT1 analysis, co-culture, in vivo tumor models, dopamine-B cell correlation\",\n      \"pmids\": [\"40023842\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor-to-JAK1 coupling mechanism not defined\", \"Single study, single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single receptor produces opposing outputs across tissues, including pro-death autophagy versus Warburg-promoting proliferation and anti- versus pro-inflammatory effects.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"G protein coupling specificity across cell types undefined\", \"No structural model of effector recruitment\", \"Determinants of context-dependent mTOR outcome unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TRAF6\", \"ARRB2\", \"PP2A\", \"TAK1\", \"IKK\", \"JAK1\", \"STAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}